Table 3.

Representative clinical trials of immune checkpoint blockade in glioma.

Registration number	New/recurrent/metastatic	Mechanism	Therapy	Number of patients	Phase
NCT02017717	Recurrent	Anti-PD1, anti-CTLA4	Nivolumab, ipilimumab, bevacizumab	n = 440	Phase III
NCT02336165	New + recurrent	Anti-PDL1	MEDI4736, Bevacizumab,	n = 84	Phase II
NCT02311920	New + recurrent	Anti-PD1, anti-CTLA4	TMZ, nivolumab, ipilimumab	n = 42	Phase I
NCT02337491	Recurrent	Anti-PD1	Pembrolizumab, bevacizumab	n = 79	Phase II
NCT01952769	Recurrent	Anti-PD1	Pidilizumab	n = 30	Phase I/II